Skip to main content
Erschienen in: Osteoporosis International 6/2017

06.03.2017 | Original Article

Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial

verfasst von: T. Imai, S. Tanaka, K. Kawakami, T. Miyazaki, H. Hagino, M. Shiraki, for the A-TOP (Adequate Treatment of Osteoporosis) Research Group

Erschienen in: Osteoporosis International | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Abstract

Summary

We assessed the health state utility value (HSUV) reductions associated with vertebral fractures using data collected in the Japanese Osteoporosis Intervention Trial-03 (JOINT-03). Our analysis revealed that assessment of HSUVs after morphometric vertebral fracture is important to capture the burden of vertebral fractures.

Introduction

Evaluation of the HSUV after fracture is important to calculate the quality-adjusted life years (QALYs) of osteoporosis patients, which is essential information in the context of health economic evaluation.

Methods

JOINT-03 study patients were aged ≥65 years and treated with risedronate and vitamin K2 or risedronate alone. Radiographic information and patient-reported outcomes measured by EQ-5D and a visual analogue scale (VAS) were assessed at registration and followed up after 6, 12, and 24 months. According to differences among the dates of these assessments and the radiographic information, we classified the follow-up HSUVs calculated based on EQ-5D results into before or after fracture categories regardless of clinical symptoms.

Results

Among 2922 follow-up HSUVs, 201 HSUVs were categorized as HSUVs that were observed after incident vertebral fractures on X-ray films. The median time from the detection of an incident vertebral fracture until the EQ-5D assessment was 53 days (25th percentile, 0 day; 75th percentile, 357 days). The impact of incident vertebral fractures on HSUVs was quantified as −0.03. Among the five health profile domains on the EQ-5D, an incident vertebral fracture had significant effects on anxiety/depression, self-care, and usual activities.

Conclusions

The results suggest that incident morphometric vertebral fracture was associated with impairment of the HSUV for patients with osteoporosis not only immediately but also several months after the fracture.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Mithal A, Ebeling P, Kyer CS (2013) Asia-Pacific Regional Audit: epidemiology, costs & burden of osteoporosis in 2013. International Osteoporosis Foundation, Nyon Mithal A, Ebeling P, Kyer CS (2013) Asia-Pacific Regional Audit: epidemiology, costs & burden of osteoporosis in 2013. International Osteoporosis Foundation, Nyon
2.
Zurück zum Zitat Tosteson ANA, Melton LJ III, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447CrossRefPubMedPubMedCentral Tosteson ANA, Melton LJ III, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Stevenson MD, Selby PL (2014) Modelling the cost effectiveness of interventions for osteoporosis: issues to consider. PharmacoEconomics 32:735–743CrossRefPubMed Stevenson MD, Selby PL (2014) Modelling the cost effectiveness of interventions for osteoporosis: issues to consider. PharmacoEconomics 32:735–743CrossRefPubMed
4.
Zurück zum Zitat Guyatt GH, Feeny DH, Patrick DL (1993) Measuring health-related quality of life. Ann Intern Med 118:622–629CrossRefPubMed Guyatt GH, Feeny DH, Patrick DL (1993) Measuring health-related quality of life. Ann Intern Med 118:622–629CrossRefPubMed
5.
Zurück zum Zitat Tosteson ANA, Hammond CS (2002) Quality-of-life assessment in osteoporosis: health-status and preference-based measures. PharmacoEconomics 20:289–303CrossRefPubMed Tosteson ANA, Hammond CS (2002) Quality-of-life assessment in osteoporosis: health-status and preference-based measures. PharmacoEconomics 20:289–303CrossRefPubMed
6.
Zurück zum Zitat Lips P, van Schoor N (2005) Quality of life in patients with osteoporosis. Osteoporos Int 16(5):447–455CrossRefPubMed Lips P, van Schoor N (2005) Quality of life in patients with osteoporosis. Osteoporos Int 16(5):447–455CrossRefPubMed
7.
Zurück zum Zitat Tosteson ANA, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ III (2001) Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 12:1042–1049CrossRefPubMed Tosteson ANA, Gabriel SE, Grove MR, Moncur MM, Kneeland TS, Melton LJ III (2001) Impact of hip and vertebral fractures on quality-adjusted life years. Osteoporos Int 12:1042–1049CrossRefPubMed
8.
Zurück zum Zitat Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22:967–982CrossRefPubMed Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22:967–982CrossRefPubMed
9.
Zurück zum Zitat Silverman S, Agodoa I, Kruse M, Parthan A, Orwoll E (2015) Denosumab for elderly men with osteoporosis: a cost-effectiveness analysis from the US payer perspective. J Osteoporos 2015:627–631 Silverman S, Agodoa I, Kruse M, Parthan A, Orwoll E (2015) Denosumab for elderly men with osteoporosis: a cost-effectiveness analysis from the US payer perspective. J Osteoporos 2015:627–631
10.
Zurück zum Zitat Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359(9319):1761–1767CrossRefPubMed Cummings SR, Melton LJ (2002) Epidemiology and outcomes of osteoporotic fractures. Lancet 359(9319):1761–1767CrossRefPubMed
11.
Zurück zum Zitat Silverman SL, Minshall ME, Shen W, Harper KD, Xie S, Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study (2001) The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 44:2611–2619CrossRefPubMed Silverman SL, Minshall ME, Shen W, Harper KD, Xie S, Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study (2001) The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 44:2611–2619CrossRefPubMed
12.
Zurück zum Zitat Delmas PD, van de Langerijt L, Watts NB, Eastell R, Genant H, Grauer A, Cahall DL (2005) Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res 20:557–563CrossRefPubMed Delmas PD, van de Langerijt L, Watts NB, Eastell R, Genant H, Grauer A, Cahall DL (2005) Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study. J Bone Miner Res 20:557–563CrossRefPubMed
13.
Zurück zum Zitat Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Lunsjo K, Thorngren KG, Sernbo I, Rehnberg C, Jonsson B (2006) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17:637–650CrossRefPubMed Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Lunsjo K, Thorngren KG, Sernbo I, Rehnberg C, Jonsson B (2006) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17:637–650CrossRefPubMed
14.
Zurück zum Zitat Borgstrom F, Lekander I, Ivergard M, Strom O, Svedbom A, Alekna V, Bianchi ML, Clark P, Curiel MD, Dimai HP, Jurisson M, Kallikorm R, Lesnyak O, McCloskey E, Nassonov E, Sanders KM, Silverman S, Tamulaitiene M, Thomas T, Tosteson ANA, Jonsson B, Kanis JA (2013) The international costs and utilities related to osteoporotic fractures study (ICUROS)—quality of life during the first 4 months after fracture. Osteoporos Int 24:811–823CrossRefPubMed Borgstrom F, Lekander I, Ivergard M, Strom O, Svedbom A, Alekna V, Bianchi ML, Clark P, Curiel MD, Dimai HP, Jurisson M, Kallikorm R, Lesnyak O, McCloskey E, Nassonov E, Sanders KM, Silverman S, Tamulaitiene M, Thomas T, Tosteson ANA, Jonsson B, Kanis JA (2013) The international costs and utilities related to osteoporotic fractures study (ICUROS)—quality of life during the first 4 months after fracture. Osteoporos Int 24:811–823CrossRefPubMed
15.
Zurück zum Zitat Hagino H, Nakamura T, Fujiwara S, Oeki M, Okano T, Teshima R (2009) Sequential change in quality of life for patients with incident clinical fractures: a prospective study. Osteoporos Int 20:695–702CrossRefPubMed Hagino H, Nakamura T, Fujiwara S, Oeki M, Okano T, Teshima R (2009) Sequential change in quality of life for patients with incident clinical fractures: a prospective study. Osteoporos Int 20:695–702CrossRefPubMed
16.
Zurück zum Zitat Hiligsmann M, Ethgen O, Richy F, Reginster JY (2008) Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int 82:288–292CrossRefPubMed Hiligsmann M, Ethgen O, Richy F, Reginster JY (2008) Utility values associated with osteoporotic fracture: a systematic review of the literature. Calcif Tissue Int 82:288–292CrossRefPubMed
17.
Zurück zum Zitat Peasgood T, Herrmann K, Kanis JA, Brazier JE (2009) An updated systematic review of health state utility values for osteoporosis related conditions. Osteoporos Int 20:853–868CrossRefPubMed Peasgood T, Herrmann K, Kanis JA, Brazier JE (2009) An updated systematic review of health state utility values for osteoporosis related conditions. Osteoporos Int 20:853–868CrossRefPubMed
18.
Zurück zum Zitat Si L, Winzenberg TM, de Graaff B, Palmer AJ (2014) A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions. Osteoporos Int 25:1987–1997CrossRefPubMed Si L, Winzenberg TM, de Graaff B, Palmer AJ (2014) A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions. Osteoporos Int 25:1987–1997CrossRefPubMed
19.
Zurück zum Zitat Cockerill W, Lunt M, Silman AJ, Cooper C, Lips P, Bhalla AK, Cannata JB, Eastell R, Felsenberg D, Gennari C, Johnell O, Kanis JA, Kiss C, Masaryk P, Naves M, Poor G, Raspe H, Reid DM, Reeve J, Stepan J, Todd C, Woolf AD, O'Neill TW (2004) Health-related quality of life and radiographic vertebral fracture. Osteoporos Int 15:113–119CrossRefPubMed Cockerill W, Lunt M, Silman AJ, Cooper C, Lips P, Bhalla AK, Cannata JB, Eastell R, Felsenberg D, Gennari C, Johnell O, Kanis JA, Kiss C, Masaryk P, Naves M, Poor G, Raspe H, Reid DM, Reeve J, Stepan J, Todd C, Woolf AD, O'Neill TW (2004) Health-related quality of life and radiographic vertebral fracture. Osteoporos Int 15:113–119CrossRefPubMed
20.
Zurück zum Zitat van Schoor NM, Ewing SK, O'Neill TW, Lunt M, Smit JH, Lips P (2008) Impact of prevalent and incident vertebral fractures on utility: results from a patient-based and a population-based sample. Qual Life Res 17(1):159–167CrossRefPubMed van Schoor NM, Ewing SK, O'Neill TW, Lunt M, Smit JH, Lips P (2008) Impact of prevalent and incident vertebral fractures on utility: results from a patient-based and a population-based sample. Qual Life Res 17(1):159–167CrossRefPubMed
21.
Zurück zum Zitat Cooper C, Jakob F, Chinn C, Martin-Mola E, Fardellone P, Adami S, Thalassinos NC, Melo-Gomes J, Torgerson D, Gibson A, Marin F (2008) Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). Osteoporos Int 19:493–501CrossRefPubMed Cooper C, Jakob F, Chinn C, Martin-Mola E, Fardellone P, Adami S, Thalassinos NC, Melo-Gomes J, Torgerson D, Gibson A, Marin F (2008) Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). Osteoporos Int 19:493–501CrossRefPubMed
22.
Zurück zum Zitat Cummings SR, San MJ, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRefPubMed Cummings SR, San MJ, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRefPubMed
23.
Zurück zum Zitat Sugimoto T, Shiraki M, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T (2013) Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial. Curr Med Res Opin 29:195–203CrossRefPubMed Sugimoto T, Shiraki M, Nakano T, Kishimoto H, Ito M, Fukunaga M, Hagino H, Sone T, Kuroda T, Nakamura T (2013) Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial. Curr Med Res Opin 29:195–203CrossRefPubMed
24.
Zurück zum Zitat Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Shiraki M, Fukunaga M (2014) Fracture risk reduction with denosumab in japanese postmenopausal women and men with osteoporosis: Denosumab fracture Intervention RandomizEd placebo Controlled Trial (DIRECT). J Clin Endocrinol Metab Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, Tanaka Y, Tanaka S, Sone T, Nakano T, Ito M, Matsui S, Yoneda T, Takami H, Watanabe K, Osakabe T, Shiraki M, Fukunaga M (2014) Fracture risk reduction with denosumab in japanese postmenopausal women and men with osteoporosis: Denosumab fracture Intervention RandomizEd placebo Controlled Trial (DIRECT). J Clin Endocrinol Metab
25.
Zurück zum Zitat Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128:793–800CrossRefPubMed Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR (1998) The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 128:793–800CrossRefPubMed
26.
Zurück zum Zitat Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15:20–26CrossRefPubMed Kanis JA, Johnell O, Oden A, Borgstrom F, Zethraeus N, Laet C, Jonsson B (2004) The risk and burden of vertebral fractures in Sweden. Osteoporos Int 15:20–26CrossRefPubMed
27.
Zurück zum Zitat Nuti R, Caffarelli C, Guglielmi G, Gennari L, Gonnelli S (2014) Undiagnosed vertebral fractures influence quality of life in postmenopausal women with reduced ultrasound parameters. Clin Orthop Relat Res 472:2254–2261CrossRefPubMedPubMedCentral Nuti R, Caffarelli C, Guglielmi G, Gennari L, Gonnelli S (2014) Undiagnosed vertebral fractures influence quality of life in postmenopausal women with reduced ultrasound parameters. Clin Orthop Relat Res 472:2254–2261CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Tanaka S, Miyazaki T, Uemura Y, Kuroda T, Miyakawa N, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M (2014) Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03). J Bone Miner Metab 32:298–304CrossRefPubMed Tanaka S, Miyazaki T, Uemura Y, Kuroda T, Miyakawa N, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M (2014) Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03). J Bone Miner Metab 32:298–304CrossRefPubMed
29.
Zurück zum Zitat Orimo H (2007) The Japanese guidelines for the prevention and treatment of osteoporosis (2006 edition). Osteoporos Jpn 15:351–355 Orimo H (2007) The Japanese guidelines for the prevention and treatment of osteoporosis (2006 edition). Osteoporos Jpn 15:351–355
30.
Zurück zum Zitat Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(2):1137–1148PubMed Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(2):1137–1148PubMed
31.
Zurück zum Zitat Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, Hamashima C, Hisashige A, Tamura M (2002) Estimating an EQ-5D population value set: the case of Japan. Health Econ 11:341–353CrossRefPubMed Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, Hamashima C, Hisashige A, Tamura M (2002) Estimating an EQ-5D population value set: the case of Japan. Health Econ 11:341–353CrossRefPubMed
32.
Zurück zum Zitat Ikeda S, Ikegami N (2001) Preference-based measure (EQ-5D). In: Ikegami N, Fukuhara S, Shimozuma K, Ikeda S (eds) QOL evaluation handbook for clinical practice (in Japanese). Igakushoin, Tokyo, pp 14–18 Ikeda S, Ikegami N (2001) Preference-based measure (EQ-5D). In: Ikegami N, Fukuhara S, Shimozuma K, Ikeda S (eds) QOL evaluation handbook for clinical practice (in Japanese). Igakushoin, Tokyo, pp 14–18
33.
Zurück zum Zitat Tanaka S, Miyazaki T, Uemura Y, Miyakawa N, Gorai I, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M (2016) Comparison of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03 (JOINT-03). J Bone Miner Metab (in press) Tanaka S, Miyazaki T, Uemura Y, Miyakawa N, Gorai I, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M (2016) Comparison of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03 (JOINT-03). J Bone Miner Metab (in press)
34.
Zurück zum Zitat Gold DT (1996) The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 18(Suppl 3):185S–189SCrossRefPubMed Gold DT (1996) The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 18(Suppl 3):185S–189SCrossRefPubMed
35.
Zurück zum Zitat Williams LJ, Pasco JA, Jackson H, Kiropoulos L, Stuart AL, Jacka FN, Berk M (2016) Depression as a risk factor for fracture in women: a 10 year longitudinal study. J Affective Disorders 192:34–40CrossRef Williams LJ, Pasco JA, Jackson H, Kiropoulos L, Stuart AL, Jacka FN, Berk M (2016) Depression as a risk factor for fracture in women: a 10 year longitudinal study. J Affective Disorders 192:34–40CrossRef
36.
Zurück zum Zitat Williams LJ, Berk M, Henry MJ, Stuart AL, Brennan SL, Jacka FN, Pasco JA (2014) Depression following fracture in women: a study of age-matched cohorts. BMJ Open 4(2) Williams LJ, Berk M, Henry MJ, Stuart AL, Brennan SL, Jacka FN, Pasco JA (2014) Depression following fracture in women: a study of age-matched cohorts. BMJ Open 4(2)
37.
Zurück zum Zitat Suzuki N, Ogikubo O, Hansson T (2009) The prognosis for pain, disability, activities of daily living and quality of life after an acute osteoporotic vertebral body fracture: its relation to fracture level, type of fracture and grade of fracture deformation. Eur Spine J 18:77–88CrossRefPubMed Suzuki N, Ogikubo O, Hansson T (2009) The prognosis for pain, disability, activities of daily living and quality of life after an acute osteoporotic vertebral body fracture: its relation to fracture level, type of fracture and grade of fracture deformation. Eur Spine J 18:77–88CrossRefPubMed
38.
Zurück zum Zitat Bernert S, Fernandez A, Haro JM, Konig HH, Alonso J, Vilagut G, Sevilla-Dedieu C, de Graaf R, Matschinger H, Heider D, Angermeyer MC (2009) Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries. Value Health 12(5):750–758CrossRefPubMed Bernert S, Fernandez A, Haro JM, Konig HH, Alonso J, Vilagut G, Sevilla-Dedieu C, de Graaf R, Matschinger H, Heider D, Angermeyer MC (2009) Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries. Value Health 12(5):750–758CrossRefPubMed
Metadaten
Titel
Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial
verfasst von
T. Imai
S. Tanaka
K. Kawakami
T. Miyazaki
H. Hagino
M. Shiraki
for the A-TOP (Adequate Treatment of Osteoporosis) Research Group
Publikationsdatum
06.03.2017
Verlag
Springer London
Erschienen in
Osteoporosis International / Ausgabe 6/2017
Print ISSN: 0937-941X
Elektronische ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-017-3966-7

Weitere Artikel der Ausgabe 6/2017

Osteoporosis International 6/2017 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.